The Zn-finger domain of MdmX suppresses cancer progression by promoting genome stability in p53-mutant cells.
The MDMX (MDM4) oncogene is amplified or overexpressed in a significant percentage of human tumors. MDMX is thought to function as an oncoprotein by binding p53 tumor suppressor protein to inhibit p53-mediated transcription, and by complexing with MDM2 oncoprotein to promote MDM2-mediated degradation of p53. However, down-regulation or loss of functional MDMX has also been observed in a variety of human tumors that are mutated for p53, often correlating with more aggressive cancers and a worse patient prognosis. We have previously reported that endogenous levels of MdmX can suppress proliferation and promote pseudo-bipolar mitosis in primary and tumor cells derived from p53-deficient mice, and that MdmX-p53 double deficient mice succumb to spontaneously formed tumors more rapidly than p53-deficient mice. These results suggest that the MdmX oncoprotein may act as a tumor-suppressor in cancers with compromised p53 function. By using orthotopic transplantation and lung colonization assays in mice we now establish a p53-independent anti-oncogenic role for MdmX in tumor progression. We also demonstrate that the roles of MdmX in genome stability and in proliferation are two distinct functions encoded by the separate MdmX protein domains. The central Zn-finger domain suppresses multipolar mitosis and chromosome loss, whereas the carboxy-terminal RING domain suppresses proliferation of p53-deficient cells. Furthermore, we determine that it is the maintenance of genome stability that underlies MdmX role in suppression of tumorigenesis in hyperploid p53 mutant tumors. Our results offer a rationale for the increased metastatic potential of p53 mutant human cancers with aberrant MdmX function and provide a caveat for the application of anti-MdmX treatment of tumors with compromised p53 activity.
Department of Cell and Developmental Biology, University of Massachusetts Medical School, Worcester, MA, USA.
Z
Z
Matijasevic
Department of Cell and Developmental Biology, University of Massachusetts Medical School, Worcester, MA, USA.
A
A
Krzywicka-Racka
Department of Cell and Developmental Biology, University of Massachusetts Medical School, Worcester, MA, USA.
G
G
Sluder
Department of Cell and Developmental Biology, University of Massachusetts Medical School, Worcester, MA, USA.
J
J
Gallant
Department of Cell and Developmental Biology, University of Massachusetts Medical School, Worcester, MA, USA.
S N
SN
Jones
Nature. 2005 Oct 13;437(7061):1043-7
16222300
CSH Protoc. 2007 Jan 01;2007:pdb.prot4660
21356931
Nature. 1995 Nov 9;378(6553):206-8
7477327
Breast Cancer Res Treat. 2006 Sep;99(1):97-101
16541312
J Biomed Biotechnol. 2011;2011:876173
21541195
J Mol Med (Berl). 2008 May;86(5):585-96
18335186
Int J Cancer. 2005 Nov 10;117(3):469-75
15906355
Mol Cell Biol. 2004 Jul;24(13):5835-43
15199139
Mol Cancer Res. 2006 Feb;4(2):79-92
16513839
Oncogene. 2002 Dec 12;21(57):8776-85
12483531
Biochim Biophys Acta. 2006 May;1764(5):929-42
16581319
Mol Biol Cell. 2002 Dec;13(12):4355-70
12475958
Mol Cancer Res. 2003 Dec;1(14):1027-35
14707286
Nat Biotechnol. 2012 May;30(5):413-21
22544022
Cancer Res. 2012 Aug 15;72(16):4074-84
22700878
Mol Cell Biol. 2008 Aug;28(15):4862-74
18541670
Annu Rev Genet. 2014;48:215-36
25292359
Cancer Chemother Pharmacol. 1989;24(3):148-54
2544306
Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14106-11
8943068
Cancer Discov. 2014 Feb;4(2):175-185
24436049
J Cell Physiol. 2009 May;219(2):288-300
19115235
Mol Cell Biol. 2008 Feb;28(4):1265-73
18039860
Nature. 1995 Nov 9;378(6553):203-6
7477326
Mol Cell Biol. 2002 Aug;22(15):5527-38
12101245
Cancer Res. 2012 Oct 15;72(20):5374-85
22942257
Oncogene. 2015 Feb 12;34(7):846-56
24608433
Genes Dev. 2008 Aug 15;22(16):2189-203
18662975
Oncogene. 2004 Jan 8;23(1):303-6
14712235
Cell Cycle. 2008 Oct;7(19):2967-73
18818521
Biochem Pharmacol. 2002 May 1;63(9):1609-17
12007564
Nature. 2006 Nov 2;444(7115):61-6
17080083
Oncogene. 2015 May 28;34(22):2943-8
25088193
Nature. 2010 Oct 7;467(7316):707-10
20861837
Nat Genet. 2001 Sep;29(1):92-5
11528400
J Biol Chem. 2002 May 31;277(22):19251-4
11953423
Science. 2005 Jan 7;307(5706):127-9
15637283
Nature. 1997 May 15;387(6630):299-303
9153396
Nat Genet. 2013 Oct;45(10):1134-40
24071852
Oncogene. 2010 Apr 22;29(16):2415-26
20140020
Proc Natl Acad Sci U S A. 1999 May 11;96(10):5516-21
10318915
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15608-12
9861017
J Cell Sci. 2007 Feb 1;120(Pt 3):371-8
17251377
Cell Death Differ. 2006 Jun;13(6):927-34
16543935
Cell. 2001 Jan 12;104(1):95-106
11163243
Genes Cancer. 2012 Mar;3(3-4):209-18
23150754
Nat Rev Mol Cell Biol. 2004 Jan;5(1):45-54
14708009
J Biol Chem. 2004 Feb 6;279(6):4877-86
14612455
Mol Cell Biol. 2000 Feb;20(3):1001-7
10629057
Cancer Res. 2002 Jun 1;62(11):3221-5
12036937
Cancer Genet Cytogenet. 1981 Jan;3(1):61-73
7272986
Cancer Res. 1978 Nov;38(11 Pt 2):4327-39
212193
Nature. 1992 Jul 2;358(6381):80-3
1614537
Oncogene. 2014 Mar 6;33(10):1336-9
23474762
Biochem Soc Trans. 2006 Nov;34(Pt 5):716-21
17052181